Perspective Therapeutics (NYSE:CATX) Stock Rating Reaffirmed by Cantor Fitzgerald

Perspective Therapeutics (NYSE:CATX - Get Free Report)'s stock had its "overweight" rating reiterated by investment analysts at Cantor Fitzgerald in a research note issued on Tuesday, Benzinga reports.

Several other equities research analysts have also commented on the stock. Lifesci Capital restated an "outperform" rating on shares of Perspective Therapeutics in a research note on Monday, May 6th. Oppenheimer cut their target price on Perspective Therapeutics from $19.00 to $17.00 and set an "outperform" rating on the stock in a research note on Tuesday, August 13th. Royal Bank of Canada reduced their price target on Perspective Therapeutics from $29.00 to $27.00 and set an "outperform" rating for the company in a research report on Friday, August 16th. Finally, Bank of America started coverage on Perspective Therapeutics in a report on Thursday, July 25th. They set a "buy" rating and a $24.00 price target on the stock. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $19.80.

Perspective Therapeutics Stock Down 10.3 %

NYSE CATX traded down $1.62 during trading hours on Tuesday, reaching $14.18. The company's stock had a trading volume of 775,476 shares, compared to its average volume of 612,095. The company has a 50-day moving average of $12.74. Perspective Therapeutics has a 52 week low of $2.05 and a 52 week high of $19.05.

Perspective Therapeutics (NYSE:CATX - Get Free Report) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.21) by $0.04. The company had revenue of $0.53 million for the quarter. As a group, equities research analysts expect that Perspective Therapeutics will post -0.87 earnings per share for the current year.

Insider Transactions at Perspective Therapeutics

In other Perspective Therapeutics news, CEO Johan M. Spoor purchased 10,000 shares of the business's stock in a transaction on Thursday, June 13th. The stock was bought at an average cost of $11.70 per share, with a total value of $117,000.00. Following the acquisition, the chief executive officer now owns 13,757 shares of the company's stock, valued at $160,956.90. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CEO Johan M. Spoor purchased 10,000 shares of the company's stock in a transaction on Thursday, June 13th. The shares were bought at an average price of $11.70 per share, with a total value of $117,000.00. Following the completion of the acquisition, the chief executive officer now owns 13,757 shares of the company's stock, valued at $160,956.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Lori A. Woods acquired 4,587 shares of the business's stock in a transaction dated Friday, June 14th. The shares were bought at an average price of $10.90 per share, with a total value of $49,998.30. Following the transaction, the director now directly owns 159,985 shares in the company, valued at approximately $1,743,836.50. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 16,387 shares of company stock valued at $184,656. Corporate insiders own 3.52% of the company's stock.

Hedge Funds Weigh In On Perspective Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Victory Capital Management Inc. purchased a new position in Perspective Therapeutics during the 2nd quarter worth approximately $117,000. Point72 DIFC Ltd purchased a new position in shares of Perspective Therapeutics during the second quarter valued at $118,000. The Manufacturers Life Insurance Company acquired a new position in Perspective Therapeutics during the second quarter valued at $188,000. ZWJ Investment Counsel Inc. purchased a new stake in Perspective Therapeutics in the 1st quarter worth about $26,000. Finally, Simplicity Wealth LLC acquired a new stake in Perspective Therapeutics during the 1st quarter worth about $40,000. Institutional investors and hedge funds own 54.66% of the company's stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.